Eagle Asset Management Inc. Increases Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Eagle Asset Management Inc. boosted its holdings in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 25.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 455,196 shares of the company’s stock after acquiring an additional 93,733 shares during the quarter. Eagle Asset Management Inc. owned about 0.76% of Phathom Pharmaceuticals worth $7,675,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Huntington National Bank raised its position in Phathom Pharmaceuticals by 62.2% in the third quarter. Huntington National Bank now owns 1,471 shares of the company’s stock valued at $27,000 after purchasing an additional 564 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Phathom Pharmaceuticals by 41.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock worth $43,000 after purchasing an additional 722 shares during the period. US Bancorp DE lifted its position in shares of Phathom Pharmaceuticals by 28.6% during the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after purchasing an additional 1,166 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Phathom Pharmaceuticals by 10.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after buying an additional 1,339 shares in the last quarter. Finally, Inspirion Wealth Advisors LLC raised its stake in shares of Phathom Pharmaceuticals by 4.3% in the second quarter. Inspirion Wealth Advisors LLC now owns 36,634 shares of the company’s stock valued at $377,000 after acquiring an additional 1,500 shares in the last quarter. 99.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $26.00 target price on shares of Phathom Pharmaceuticals in a report on Friday, September 13th. HC Wainwright reiterated a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Monday, August 12th. Finally, The Goldman Sachs Group lifted their price objective on shares of Phathom Pharmaceuticals from $10.00 to $12.00 and gave the company a “neutral” rating in a research note on Friday, August 9th.

Phathom Pharmaceuticals Trading Down 1.2 %

NASDAQ:PHAT opened at $9.34 on Monday. The stock’s 50 day simple moving average is $15.65 and its 200-day simple moving average is $13.35. Phathom Pharmaceuticals, Inc. has a 12-month low of $6.07 and a 12-month high of $19.71. The firm has a market cap of $638.67 million, a P/E ratio of -1.64 and a beta of 0.72.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.